Blog | Drive Therapeutics

Drive Therapeutics awarded a Phase 1 SBIR from the NSF

Drive was recently awarded a $256,000 Phase 1 SBIR grant from the NSF to help continue development of our novel, aptamer based inhibitors...

Drive Receives Funding from NC Biotech Center

Drive Therapeutics of Research Triangle Park received $100,000 to develop a novel nucleic acid therapy to block angiogenesis,...

Welcome Doug Gooding to the Drive Therapeutics Team!

Doug has agreed to join the team as CEO and help us navigate fundraising, early stage company formation, and relationship formation...

Go Aptamers Go!!

Exciting news out of the University of Louisville.....

Catch Up With Us on Gust

As a fledgling biotech startup, we are looking for ways to raise funding and meet potential investors while #stayingathome. We have...